US FDA halts new enrolment in GSK's TIDE trial
This article was originally published in Scrip
Executive Summary
The US FDA has put GlaxoSmithKline's global TIDE trial, comparing cardiovascular safety of its diabetes drug Avandia (rosiglitazone) versus Takeda's Actos (pioglitazone), on a "partial clinical hold", meaning that new patients cannot be enrolled in the trial until the agency gives the go-ahead. Patients already enrolled can continue in the study.